Cargando…
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
Autores principales: | Beinfeld, Molly, Atlas, Steven J, Touchette, Daniel, McKenna, Avery, Rind, David, Pearson, Steven D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391138/ https://www.ncbi.nlm.nih.gov/pubmed/34057394 http://dx.doi.org/10.18553/jmcp.2021.27.6.797 |
Ejemplares similares
-
Nadofaragene Firadenovec: First Approval
por: Lee, Arnold
Publicado: (2023) -
Correction to: Nadofaragene Firadenovec: First Approval
por: Lee, Arnold
Publicado: (2023) -
The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020) -
Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022) -
The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)